for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Regeneron Pharmaceuticals Inc

REGN.O

Latest Trade

450.57USD

Change

-2.62(-0.58%)

Volume

1,193,692

Today's Range

445.57

 - 

457.17

52 Week Range

418.01

 - 

664.64

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
453.19
Open
455.84
Volume
1,193,692
3M AVG Volume
21.34
Today's High
457.17
Today's Low
445.57
52 Week High
664.64
52 Week Low
418.01
Shares Out (MIL)
107.13
Market Cap (MIL)
48,270.42
Forward P/E
10.13
Dividend (Yield %)
--

Next Event

Regeneron Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual)

Latest Developments

More

EMA Issues Advice On Regeneron's Antibody Cocktail For Certain COVID-19 Patients

EMA Issues Advice On Use Of REGN-COV2 Antibody Combination

Regeneron Pharmaceuticals Says Independent Data Monitoring Committee Finds Clear Efficacy For Regen-Cov In Phase 3 Covid-19 Outpatient Outcomes Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Industry

Biotechnology & Drugs

Contact Info

777 Old Saw Mill River Rd

TARRYTOWN, NY

10591-6717

United States

+1.914.8477000

https://www.regeneron.com/

Executive Leadership

P. Roy Vagelos

Chairman of the Board, Director

Leonard S. Schleifer

President, Chief Executive Officer, Director

George D. Yancopoulos

President, Chief Scientific Officer, Director

Robert E. Landry

Chief Financial Officer, Executive Vice President - Finance

Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

Key Stats

1.96 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

6.7K

2019

7.9K

2020

8.5K

2021(E)

11.8K
EPS (USD)

2018

22.840

2019

24.670

2020

31.470

2021(E)

44.478
Price To Earnings (TTM)
14.69
Price To Sales (TTM)
5.68
Price To Book (MRQ)
4.37
Price To Cash Flow (TTM)
12.88
Total Debt To Equity (MRQ)
24.45
LT Debt To Equity (MRQ)
24.45
Return on Investment (TTM)
25.86
Return on Equity (TTM)
21.98

Latest News

Latest News

EU regulator advises use of Regeneron antibody cocktail for COVID-19

Europe's medicines regulator said on Friday an antibody drug combination developed by Regeneron Pharmaceuticals can be used to treat COVID-19 patients who do not require oxygen support and are at high risk of progressing to severe illness.

EU regulator endorses Regeneron antibody cocktail to treat COVID-19

Europe's medicines regulator said on Friday that an antibody drug combination developed by Regeneron Pharmaceuticals can be used to treat COVID-19 patients who do not require oxygen support and are at high risk of progressing to severe illness.

Regeneron to stop giving placebo in COVID-19 drug trial after 'clear efficacy'

Regeneron Pharmaceuticals said on Thursday that an independent panel found the company's COVID-19 antibody cocktail to have "clear clinical efficacy" in reducing the rates of hospitalization and deaths in patients.

Coronavirus-hit Czechs order Regeneron antibody drug ahead of EU registration

The Czech Republic, hard-hit by the COVID-19 pandemic, has ordered 12,000 doses of an antibody treatment made by Regeneron ahead of its registration by European authorities and will start receiving it in March, Prime Minister Andrej Babis said on Saturday.

Amgen loses bid to revive patents for cholesterol drug Repatha

A federal appeals court has rejected a bid by Amgen Inc to revive patents on its cholesterol drug Repatha after they were ruled invalid by a district court, a victory for Regeneron Pharmaceuticals Inc and Sanofi SA, which sell a rival drug.

Czech health ministry recommends use of Lilly and Regeneron COVID-19 antibody therapies

The Czech Health Ministry will recommend the use of COVID-19 therapies that contain casirivimab/imdevimab and bamlavinimab antibodies ahead of standard approval, the ministry said on Monday.

Italy's regulator approves conditional use of COVID-19 antibody therapies

Italy's medicines regulator AIFA has given the green light for emergency use of COVID-19 antibody therapies developed by U.S drugmakers Eli Lilly and Regeneron, it said on Friday.

Regeneron quarterly profit beats on strong drug sales

Regeneron Pharmaceuticals Inc's quarterly profit surged past estimates on Friday, benefiting from a recovery in demand for its flagship eye drug and a jump in sales of its eczema drug, sending the drugmaker's shares up 3% before the bell.

Regeneron quarterly profit rises 45% on Eylea strength

Regeneron Pharmaceuticals Inc on Friday reported a 45% rise in quarterly profit, benefiting from a recovery in demand for its flagship eye drug, Eylea, which took a hit last year due to the pandemic.

EU regulator reviewing Lilly, Regeneron COVID-19 antibody therapies

Europe's drugs regulator said on Thursday it was reviewing data on COVID-19 antibody therapies developed by U.S. drugmakers Eli Lilly and Regeneron for use in some patients.

EU regulator to begin review of Lilly, Regeneron COVID-19 antibody therapies

Europe's drugs regulator said on Thursday it will begin reviewing data on U.S. drugmakers Eli Lilly and Regeneron's combination therapies of antibody-based treatments for use in COVID-19 patients.

EMA starts rolling review of Regeneron's COVID-19 antibody

Europe's health regulator on Monday said it had started a real-time review of Regeneron Pharmaceuticals Inc's antibody therapy for the treatment and prevention of COVID-19.

Regeneron COVID-19 drug cocktail combats South Africa variant, Lilly's does not - study

Laboratory testing found that Regeneron Pharmaceuticals Inc's COVID-19 antibody cocktail can combat a coronavirus variant first found in South Africa, but a similar drug from Eli Lilly and Co is inactive against it, according to a study released on Tuesday.

Eli Lilly, Regeneron's COVID-19 treatments may be weaker against South Africa variant-study

COVID-19 antibody drugs developed by Eli Lilly and Co and Regeneron may be weaker against a new coronavirus variant found in South Africa, according to a study released on Tuesday based on laboratory tests.

Regeneron study shows antibody cocktail effective in preventing COVID-19 infection

Regeneron Pharmaceuticals Inc said on Tuesday its antibody cocktail was found effective in preventing COVID-19 in people exposed to those infected with the new coronavirus in an ongoing late stage trial.

Regeneron's antibody cocktail effective in preventing COVID-19 infection - study

Regeneron Pharmaceuticals Inc said on Tuesday its antibody cocktail was effective in preventing COVID-19 in people exposed to those infected with the new coronavirus, based on interim results from a late-stage study.

U.S. to buy 1.25 million additional doses of Regeneron's COVID-19 antibody cocktail

The U.S. government will buy 1.25 million additional doses of Regeneron Pharmaceuticals' COVID-19 antibody cocktail for about $2.63 billion, bringing the total supply of the treatment to more than 1.5 million doses.

U.S. government to buy 1.25 mln additional doses of Regeneron's COVID-19 antibody cocktail

The U.S. government will buy 1.25 million additional doses of Regeneron Pharmaceuticals Inc's COVID-19 antibody cocktail to be used in non-hospitalized COVID-19 patients, the drugmaker said on Tuesday.

UPDATE 1-Regeneron says antibodies likely potent vs virus variants, Lilly concerned about S. Africa version

Regeneron Pharmaceuticals Inc's dual antibody therapy for COVID-19 will likely be effective against new variants of the coronavirus identified so far, the drugmaker's chief executive officer said on Monday.

BRIEF-Regeneron Exec Says Its Antibody Cocktail Therapy For COVID-19 Will Likely Help Against Variants Of The Virus - J.P.Morgan Conf

* REGENERON EXECUTIVE SAYS ITS ANTIBODY COCKTAIL THERAPY AGAINST COVID-19 WILL LIKELY HELP AGAINST VARIANTS OF THE VIRUS - J.P.MORGAN CONF

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up